IBOV 167,537.95 ▼ 1.34% COLCAP 2,452.46 — — IPC MEX 69,770.84 ▼ 0.88% MERVAL 2,848,945 — — USD/BRL5.85▼ 0.62% USD/MXN18.90▲ 0.24% USD/CLP1,007▲ 1.47% USD/COP3,347▲ 1.20% USD/PEN3.41▲ 0.05% USD/ARS1,559▼ 0.02% USD/UYU40.61▲ 3.19% USD/PYG6,212▲ 2.85% USD/BOB11.64▲ 3.07% USD/DOP60.01▼ 0.32% USD/CRC441.73▲ 2.50% USD/GTQ7.64▲ 3.23% USD/HNL26.89▼ 0.10% USD/NIO36.62▲ 0.26% USD/VES913.46▼ 0.35% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.39▲ 2.28% USD/TTD6.70▲ 2.24% EUR/BRL6.42▲ 1.12% BRENT 89.37 ▼ 2.81% WTI 82.29 ▼ 1.17% IRON ORE 161.91 — — COPPER 5.67 ▲ 0.12% GOLD 3,737 ▼ 0.13% SILVER 45.32 ▲ 0.70% SOY 1,217 ▼ 0.02% CORN 434.50 ▼ 0.23% WHEAT 587.50 ▲ 3.07% COFFEE 276.05 ▼ 3.68% SUGAR 18.07 ▼ 0.55% ORANGE JUICE 129.10 ▼ 4.37% COTTON 80.23 ▲ 3.76% COCOA 5,027 ▼ 0.06% BEEF 219.90 ▲ 0.51% CATTLE 336.85 ▲ 0.38% LITHIUM 55.57 ▼ 1.51% PETR4 43.17 ▼ 1.84% VALE3 59.00 ▼ 2.22% ITUB4 40.19 ▼ 1.71% BBDC4 14.08 ▼ 2.29% ABEV3 16.07 ▲ 0.88% BBAS3 14.12 ▼ 3.42% B3SA3 14.30 ▼ 2.39% WEGE3 51.38 ▲ 0.45% PRIO3 61.87 ▼ 3.27% SUZB3 55.60 ▲ 0.38% RENT3 29.45 ▼ 0.71% AZZA3 15.78 ▲ 0.90% CSAN3 3.13 ▼ 3.69% RAIZ4 18.49 ▼ 3.24% PCAR3 2.99 ▲ 3.46% GMAT3 4.05 ▼ 3.11% PSSA3 44.66 ▼ 2.74% CVCB3 0.78 — 0.00% POSI3 3.17 ▲ 1.28% SLCE3 17.88 ▼ 1.00% NATU3 4.78 ▲ 0.63% BRKM5 2.63 ▼ 4.36% RANI3 8.07 ▼ 1.82% IBOV 167,537.95 ▼ 1.34% COLCAP 2,452.46 — — IPC MEX 69,770.84 ▼ 0.88% MERVAL 2,848,945 — — USD/BRL 5.85 ▲ 1.14% USD/MXN 18.91 ▲ 0.29% USD/CLP 1,007 ▲ 1.47% USD/COP 3,347 ▲ 1.20% USD/PEN 3.41 ▲ 0.05% USD/ARS 1,559 ▼ 0.02% USD/UYU 40.61 ▲ 3.30% USD/PYG 6,212 ▲ 2.85% USD/BOB 11.64 ▲ 3.02% USD/DOP 60.01 ▼ 0.32% USD/CRC 441.73 ▲ 2.49% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.89 ▼ 0.14% USD/NIO 36.62 ▲ 0.26% USD/VES 913.46 ▼ 0.35% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.39 ▲ 2.28% USD/TTD 6.70 ▲ 2.24% EUR/BRL 6.42 ▲ 1.12% BRENT 89.37 ▼ 2.81% WTI 82.29 ▼ 1.17% IRON ORE 161.91 — — COPPER 5.67 ▲ 0.12% GOLD 3,737 ▼ 0.13% SILVER 45.32 ▲ 0.70% SOY 1,217 ▼ 0.02% CORN 434.50 ▼ 0.23% WHEAT 587.50 ▲ 3.07% COFFEE 276.05 ▼ 3.68% SUGAR 18.07 ▼ 0.55% ORANGE JUICE 129.10 ▼ 4.37% COTTON 80.23 ▲ 3.76% COCOA 5,027 ▼ 0.06% BEEF 219.90 ▲ 0.51% CATTLE 336.85 ▲ 0.38% LITHIUM 55.57 ▼ 1.51% PETR4 43.17 ▼ 1.84% VALE3 59.00 ▼ 2.22% ITUB4 40.19 ▼ 1.71% BBDC4 14.08 ▼ 2.29% ABEV3 16.07 ▲ 0.88% BBAS3 14.12 ▼ 3.42% B3SA3 14.30 ▼ 2.39% WEGE3 51.38 ▲ 0.45% PRIO3 61.87 ▼ 3.27% SUZB3 55.60 ▲ 0.38% RENT3 29.45 ▼ 0.71% AZZA3 15.78 ▲ 0.90% CSAN3 3.13 ▼ 3.69% RAIZ4 18.49 ▼ 3.24% PCAR3 2.99 ▲ 3.46% GMAT3 4.05 ▼ 3.11% PSSA3 44.66 ▼ 2.74% CVCB3 0.78 — 0.00% POSI3 3.17 ▲ 1.28% SLCE3 17.88 ▼ 1.00% NATU3 4.78 ▲ 0.63% BRKM5 2.63 ▼ 4.36% RANI3 8.07 ▼ 1.82%
since 2009
Thursday, November 19, 2026

Brazil Business - Brazil

Brazil’s Oncoclínicas Sells Saudi Stake for $6.5 Million

By · · 5 min read
Oncoclínicas Sells Saudi Stake for US.5 Million
It operates a network of oncology clinics providing specialised cancer treatment across Brazil.

Brazil · Business

Key Facts

—Sale price. US$6.5 million, paid cash upfront by the Saudi partners.

Free daily brief — no card needed
Get every Brazil story in one morning email
We build you a personalized brief around the topics you follow — free for 7 days. Love it? Your first month after that is US$1.

—Venture sold. Specialized Medical Treatment Company, an oncology-care firm in Riyadh.

—Original ambition. Projected US$550 million in revenue and US$150 million in EBITDA within five years of launch.

—Brazil debt load. Roughly R$5.1 billion (US$1.01 billion) in financial debt.

—Recent loss. Net loss of R$438.7 million (US$86.5 million) in the first quarter of 2026.

Oncoclínicas, Brazil’s largest cancer-treatment network, has sold its entire stake in a Saudi Arabian oncology joint venture for US$6.5 million in upfront cash, the company confirmed on 22 July 2026.

What Oncoclínicas Does and Why the Saudi Venture Mattered

Oncoclínicas is a São Paulo-headquartered company that runs a network of specialized cancer clinics and hospitals across Brazil, treating hundreds of thousands of patients annually. It went public with an aggressive growth story that included taking its oncology-care model abroad.

The Saudi project, structured through a 51/49 joint venture called the Specialized Medical Treatment Company, was launched with Al Faisaliah Group Holding Company and its pharmaceutical arm, Advanced Drug Company for Pharmaceuticals. The original plan envisioned building an ambulatory oncology unit in Riyadh and later expanding to Jeddah and Mecca.

A Small Divestment That Signals a Bigger Deleveraging Story

The US$6.5 million exit price is modest compared with the venture’s original projections, which forecast roughly US$550 million in revenue and US$150 million in EBITDA within five years. Oncoclínicas had expected to invest between US$10 million and US$20 million over three years in the first phase alone.

Management said the sale aims to simplify the portfolio, focus on Brazil, and avoid sinking more capital into a foreign project while the company works through a severe cash crunch. The Saudi venture had already been deprioritized, and Oncoclínicas had frozen further remittances to the center.

The Debt and Liquidity Crisis at Home

Oncoclínicas sold its Saudi stake for US$6.5 million, weighed down by financial debt of approximately R$5.1 billion (US$1.01 billion). The company is negotiating with creditors and suppliers while hunting for asset sales and fresh capital.

In the first quarter of 2026, the company posted a net loss of R$438.7 million (US$86.5 million), compared with a net loss of R$131.9 million in Q1 2025, which is about 3.3 times larger. The deteriorating results have accelerated a broader restructuring effort.

Background: How a Brazilian Healthcare Champion Stumbled

For years, Oncoclínicas was a darling of Brazil’s healthcare sector, consolidating dozens of clinics and attracting international investors with a story of rising cancer incidence and a fragmented market ripe for professionalization. The Saudi venture, announced with fanfare, was meant to prove the model could travel beyond Latin America.

But rapid expansion and high leverage left the company exposed when interest rates rose and operational costs climbed. By early 2026, supplier payment delays and mounting short-term obligations forced management to seek court protection, a process known in Brazil as judicial recovery that gives a company breathing room to restructure debts without immediate creditor enforcement.

Our reporting has shown that the core clinics remain full and cancer volumes in Brazil continue to grow, making the crisis primarily a balance-sheet and cost-structure problem rather than a collapse in demand.

Rescue Talks and What Comes Next for Oncoclínicas

Several turnaround scenarios are on the table. One proposal involves a capital increase of roughly R$2 billion (US$394 million) (US$394 million) tied to debt conversion and new money.

Another reported framework would bring in Brazilian insurer Porto with a potential injection of up to R$1 billion (US$197 million) and a new corporate structure to isolate part of the operations.

The Saudi exit, while small in dollar terms, clears one distraction from a management team that must now stabilize a domestic network serving thousands of cancer patients. For foreign investors watching Brazil’s healthcare sector, the sale marks a sober milepost in a deleveraging story that is still unfolding.

What It Means for Expats and Investors in Brazil

For expats and foreign residents who rely on private healthcare in Brazil, Oncoclínicas remains one of the country’s most important cancer-care providers, and its restructuring does not mean clinics are closing. The judicial recovery process is designed to keep operations running while debts are renegotiated, so patient care should continue largely uninterrupted.

For investors, the Saudi sale is a clear signal that the company is retreating to its core market and prioritizing balance-sheet repair over growth. Anyone holding Brazilian healthcare stocks or private credit exposure should watch the Porto talks closely, as a credible rescue could stabilize the company, while failure to reach a deal would raise the risk of a deeper restructuring or asset fire sales.

Background: our doing business in brazil a complete guide for foreign entrepreneurs guide.

Frequently Asked Questions

What does Oncoclínicas do?

Oncoclínicas is Brazil's largest dedicated cancer-treatment network, operating clinics and hospitals that provide oncology care, chemotherapy, radiotherapy, and related services across the country. It treats hundreds of thousands of patients annually and is headquartered in São Paulo.

Why did Oncoclínicas sell its Saudi venture?

The company sold the stake to simplify its portfolio, focus on its core Brazilian business, and avoid putting more capital into a foreign project while it addresses a heavy debt load and liquidity crisis. The Saudi operation had already been deprioritized and further remittances were frozen.

How much debt does Oncoclínicas have?

The company entered judicial recovery in July 2026 with roughly R$5.1 billion (US$1.01 billion) in financial debt and reported a first-quarter net loss of R$438.7 million (US$86.5 million). Several rescue proposals are under discussion, including a potential capital increase and a partnership with Brazilian insurer Porto.

RT
Ask Rio Times
Latin American markets, currencies and companies.
Open the full Ask Rio Times →

Connected Coverage

Santander H1 Profit Hits US$10.3 Billion on Brazil Push

Brazil’s União Brasil Drops Flávio Bolsonaro’s 2026 Bid

Sources: Oncoclínicas.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.